Search research articles
Contact Us
Filters
Showing results (1-10 of 176) with videos related to
Page
of 18
Sort By:
Muscle & Nerve
|
August 30, 2025
Cardiac Troponin T in Tofersen-Treated SOD1 ALS Patients: Beginning to Resolve the Catch-22 of Identifying Treatment Responsive Biomarkers in ALS Drug Development
James D Berry, Robert Bowser
Neurology
|
January 11, 2019
Heterogeneity, urgency, generalizability, and enrollment: The HUGE balance in ALS trials
Chafic Karam, James D Berry
Neurology
|
April 15, 2014
Reevaluating the risk of DVT in people with ALS: weak in the knees and DVTs
James D Berry, Lawrence Korngut
Neurology
|
August 10, 2005
A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster
James D Berry, Karin Lottrup Petersen
The Journal of Clinical Psychiatry
|
December 21, 2023
The Intense Psychological Burden of ALS, the Enduring Strength of People Living With ALS, and the Tools We Can Use to Help
Doreen T Ho, James D Berry
Clinical Investigation
|
May 1, 2012
New considerations in the design of clinical trials for amyotrophic lateral sclerosis
James D Berry, Merit E Cudkowicz
Clinical Investigation
|
February 17, 2017
Outcome measures in amyotrophic lateral sclerosis clinical trials
Sabrina Paganoni, Merit Cudkowicz, James D Berry
JAMA
|
June 18, 2025
CNM-Au8 in Amyotrophic Lateral Sclerosis-Reply
James D Berry, Nicholas Maragakis, Sabrina Paganoni
Muscle & Nerve
|
February 7, 2026
Survival of Intravenous Edaravone-Treated Patients With ALS: Evidence From Administrative Claims Analyses
Benjamin Rix Brooks, James D Berry, Malgorzata Ciepielewska
Seminars in Neurology
|
October 28, 2015
Amyotrophic Lateral Sclerosis: Review
Johnny S Salameh, Robert H Brown, James D Berry
Page
of 18
Search research articles
Search
Showing results (1-10 of 176) with videos related to
Sort By:
Page
of 18
Muscle & Nerve
|
August 30, 2025
Cardiac Troponin T in Tofersen-Treated SOD1 ALS Patients: Beginning to Resolve the Catch-22 of Identifying Treatment Responsive Biomarkers in ALS Drug Development
James D Berry, Robert Bowser
Neurology
|
January 11, 2019
Heterogeneity, urgency, generalizability, and enrollment: The HUGE balance in ALS trials
Chafic Karam, James D Berry
Neurology
|
April 15, 2014
Reevaluating the risk of DVT in people with ALS: weak in the knees and DVTs
James D Berry, Lawrence Korngut
Neurology
|
August 10, 2005
A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster
James D Berry, Karin Lottrup Petersen
The Journal of Clinical Psychiatry
|
December 21, 2023
The Intense Psychological Burden of ALS, the Enduring Strength of People Living With ALS, and the Tools We Can Use to Help
Doreen T Ho, James D Berry
Clinical Investigation
|
May 1, 2012
New considerations in the design of clinical trials for amyotrophic lateral sclerosis
James D Berry, Merit E Cudkowicz
Clinical Investigation
|
February 17, 2017
Outcome measures in amyotrophic lateral sclerosis clinical trials
Sabrina Paganoni, Merit Cudkowicz, James D Berry
JAMA
|
June 18, 2025
CNM-Au8 in Amyotrophic Lateral Sclerosis-Reply
James D Berry, Nicholas Maragakis, Sabrina Paganoni
Muscle & Nerve
|
February 7, 2026
Survival of Intravenous Edaravone-Treated Patients With ALS: Evidence From Administrative Claims Analyses
Benjamin Rix Brooks, James D Berry, Malgorzata Ciepielewska
Seminars in Neurology
|
October 28, 2015
Amyotrophic Lateral Sclerosis: Review
Johnny S Salameh, Robert H Brown, James D Berry
Page
of 18